Literature DB >> 20388119

In vitro differentiation of human amniotic fluid-derived cells: augmentation towards a neuronal dopaminergic phenotype.

Shona Pfeiffer1, David McLaughlin.   

Abstract

Amniotic fluid is known to yield a number of cell types which are multipotent, ethically derived, genetically stable, easily grown, expanded and possess favourable immunogenicity, which has resulted in an increasing interest for use in various neuronal disorders such as Parkinson's disease. The neuronal potential of cells derived from the adherent fraction of amniotic fluid, routinely taken by amniocentesis, are least explored. The aim of the present study was to investigate the capacity of these cells for neuronal and dopaminergic differentiation using in vitro differentiation protocols with canonical inductive factors not previously tested. To do this, samples derived from multiple donors were grown under four conditions: standard serum-containing media, NB (neurobasal) media designed specifically for propagation and maintenance of neuronal cells, NB media with addition of retinoic acid and BDNF (brain-derived neurotrophic factor) for NI (neuronal induction), and NB media with addition of FGF8 (fibroblast growth factor-8) and Shh (sonic hedgehog) after NI. Our results showed the presence of multiple neuronal markers after growth in serum-containing medium [TUJ1, MAP2, NF-M, TH (tyrosine hydroxylase)], which was significantly up-regulated after serum withdrawal in NB medium alone with induction of NeuN (neuronal nuclei) and NSE (neuron-specific enolase). NI and DA.I (dopaminergic induction) was accompanied by further increases in expression and a distinct transition to a sustained neuronal morphology. Western blot analysis confirmed increasing TH expression and NURR1, expressed in base serum-containing media, found to be down-regulated after induction. In conclusion, these cells possess a highly favourable base neuronal and dopaminergic prepotential, which may easily be accentuated by standard induction protocols.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388119     DOI: 10.1042/CBI20090445

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  7 in total

Review 1.  Carcinogenesis: the cancer cell-mast cell connection.

Authors:  Maria-Angeles Aller; Ana Arias; Jose-Ignacio Arias; Jaime Arias
Journal:  Inflamm Res       Date:  2018-11-20       Impact factor: 4.575

Review 2.  Amniotic fluid stem cells to study mTOR signaling in differentiation.

Authors:  Margit Rosner; Katharina Schipany; Bharanidharan Shanmugasundaram; Gert Lubec; Oliver Brandau; Markus Hengstschläger
Journal:  Organogenesis       Date:  2012-07-01       Impact factor: 2.500

Review 3.  Amniotic fluid-derived stem cells for cardiovascular tissue engineering applications.

Authors:  Jennifer Petsche Connell; Gulden Camci-Unal; Ali Khademhosseini; Jeffrey G Jacot
Journal:  Tissue Eng Part B Rev       Date:  2013-03-14       Impact factor: 6.389

4.  Pathological axes of wound repair: gastrulation revisited.

Authors:  Maria-Angeles Aller; Jose-Ignacio Arias; Jaime Arias
Journal:  Theor Biol Med Model       Date:  2010-09-14       Impact factor: 2.432

5.  The Amazing Power of Cancer Cells to Recapitulate Extraembryonic Functions: The Cuckoo's Tricks.

Authors:  Jose-Ignacio Arias; Maria-Angeles Aller; Isabel Prieto; Ana Arias; Zoe de Julian; Heping Yang; Jaime Arias
Journal:  J Oncol       Date:  2011-09-28       Impact factor: 4.375

6.  Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis.

Authors:  Margit Rosner; Helmut Dolznig; Katharina Schipany; Mario Mikula; Oliver Brandau; Markus Hengstschläger
Journal:  Oncotarget       Date:  2011-09

7.  Neuronal cell differentiation of mesenchymal stem cells originating from canine amniotic fluid.

Authors:  Eun Young Kim; Kyung-Bon Lee; Jung Yu; Ji Hye Lee; Keun Jung Kim; Kil-Woo Han; Kang-Sun Park; Dong-Soo Lee; Min Kyu Kim
Journal:  Hum Cell       Date:  2013-10-29       Impact factor: 4.174

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.